NKG2-D Inhibitors
The class of chemicals known as NKG2-D Inhibitors comprises a diverse array of compounds that can either directly or indirectly modulate the activity of Natural Killer Group 2, member D (NKG2-D), a crucial receptor involved in immune responses. These inhibitors offer insights into pharmacological strategies for controlling NKG2-D-mediated cellular responses. Several compounds within this class, such as AZD1480, Tofacitinib, Ruxolitinib, Fedratinib, Baricitinib, INCB018424, and others, indirectly inhibit NKG2-D signaling by targeting the JAK/STAT pathway. These inhibitors disrupt the phosphorylation events crucial for NKG2-D activation, underscoring the intricate cross-talk between signaling pathways and providing pharmacological approaches to modulate NKG2-D-mediated immune responses. The indirect nature of inhibition suggests the involvement of interconnected signaling networks in the regulation of NKG2-D.
Furthermore, inhibitors like Sotrastaurin, TAK-659, Ibrutinib, Entospletinib, Dasatinib, and Fostamatinib indirectly modulate NKG2-D signaling by targeting kinases such as PKC, Syk, BTK, and Src family kinases. These inhibitors disrupt downstream signaling pathways linked to NKG2-D activation, offering indirect means to attenuate NKG2-D-mediated cellular responses. This highlights the diverse regulatory mechanisms influencing NKG2-D and provides pharmacological avenues for controlling immune responses associated with NKG2-D activation. In conclusion, the NKG2-D Inhibitors class presents a valuable toolkit for researchers exploring the modulation of NKG2-D-mediated immune responses. These inhibitors provide a foundation for further investigations into the precise regulatory mechanisms governing NKG2-D and its role in immune surveillance.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $122.00 $1051.00 | 11 | |
AZD1480 is a JAK/STAT pathway inhibitor that indirectly inhibits NKG2-D signaling. By targeting JAK kinases, AZD1480 disrupts the phosphorylation events crucial for NKG2-D activation, thereby modulating the downstream signaling cascades involved in immune responses. This indirect inhibition highlights the interconnected nature of signaling pathways and offers a potential strategy for attenuating NKG2-D-mediated cellular responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib, a JAK1/JAK2 inhibitor, indirectly inhibits NKG2-D signaling by interfering with the JAK/STAT pathway. Through JAK inhibition, Ruxolitinib disrupts the phosphorylation events necessary for NKG2-D activation, modulating downstream signaling cascades involved in immune responses. This indirect inhibition underscores the interconnectedness of signaling pathways and offers a potential avenue for regulating NKG2-D-mediated cellular responses. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
TG101348, a JAK2 inhibitor, indirectly inhibits NKG2-D signaling by targeting the JAK/STAT pathway. By inhibiting JAK2, TG101348 disrupts the phosphorylation events crucial for NKG2-D activation, leading to the modulation of downstream signaling cascades involved in immune responses. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Baricitinib, a JAK1/JAK2 inhibitor, indirectly inhibits NKG2-D signaling by targeting the JAK/STAT pathway. Through JAK inhibition, Baricitinib disrupts the phosphorylation events essential for NKG2-D activation, modulating downstream signaling cascades involved in immune responses. This indirect inhibition highlights the interconnected nature of signaling pathways and offers a pharmacological approach to regulate NKG2-D-mediated cellular responses. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a PKC inhibitor that indirectly modulates NKG2-D signaling. By inhibiting PKC, Sotrastaurin influences downstream signaling pathways linked to NKG2-D activation, providing an indirect means to attenuate NKG2-D-mediated cellular responses. This indirect modulation highlights the involvement of PKC in the regulation of NKG2-D signaling and offers a potential pharmacological approach for controlling immune responses associated with NKG2-D activation. | ||||||
GS 9973 | 1229208-44-9 | sc-490337 sc-490337A sc-490337B sc-490337C sc-490337D | 10 mg 50 mg 100 mg 500 mg 1 g | $250.00 $878.00 $1353.00 $5500.00 $9000.00 | ||
GS 9973 is a Syk inhibitor that indirectly modulates NKG2-D signaling. By targeting Syk, GS 9973 disrupts downstream signaling pathways associated with NKG2-D activation, providing an indirect means to influence NKG2-D-mediated cellular responses. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, indirectly modulates NKG2-D signaling. By inhibiting Src family kinases, Dasatinib disrupts downstream signaling pathways linked to NKG2-D activation, offering an indirect means to attenuate NKG2-D-mediated cellular responses. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
R788 is a Syk inhibitor that indirectly modulates NKG2-D signaling. By targeting Syk, R788 disrupts downstream signaling pathways associated with NKG2-D activation, providing an indirect means to influence NKG2-D-mediated cellular responses. | ||||||